Sign in
CompletedNo phase

Tocilizumab in Corticosteroid-Resistant Graves' Orbitopathy (Thyroid Eye Disease)

Key facts

Who runs it
Medical University of Warsaw
Where
Poland1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
32 people enrolled
Started
20 May 2021
Ended
20 May 2025
Type of study
Observational
Treatments tested
  • Tocilizumab
Record updated
4 June 2026

Who can take part

Age
18 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 36 criteriaShow less

Who can take part

  • Written informed consent
  • Male or female, 18-80 years old
  • Patients with active (Clinical Activity Score ≥ 3 in 7-item scale) and moderate-to-severe GO, diagnosed according to the EUGOGO guidelines, after the completion of MP pulse treatment, WITH; o Deterioration of GO (in 1 or 2 eyes) when two of the following occurred:
  • increase in palpebral aperture by at least 2 mm
  • deterioration in CAS by at least 2 points (7-point CAS)
  • increase in exophthalmos by at least 2 mm
  • worsening of diplopia (appearance or change in the degree)
  • worsening in ocular motility by 8o; o Incomplete response in both eyes to intravenous methylprednisolone pulse therapy; defined changes smaller than previously defined in any of the mentioned parameters
  • Euthyroid for at least 6-8 weeks (serum free hormone concentrations within 30% of normal range) on either anti-thyroid medications (tyonamides) to control hyperthyroidism or L-thyroxine for replacement therapy for hypothyroidism
  • Negative pregnancy test in women of fertile age
  • All female patients of fertile age must use a reliable contraceptive method to prevent pregnancy during the study period, and at least during a period of six months following the last dose of the investigational medicinal product

Who cannot take part

  • Patients who could need treatment with radioactive iodine or thyroidectomy during the study
  • Treatment with any biological therapy at any time
  • Required management of infections, as follows: currently on any suppressive therapy for a chronic infection, hospitalization for treatment of infection within 60 days before Day 0, use of parenteral antibiotics within 60 days before Day 0, use of oral antibiotics within 30 days before Day 0
  • Administration of live vaccines given within 30 days prior to administration of (Day 0) or concurrently with tocilizumab (during study)
  • Current drug or alcohol abuse or dependence
  • Active infection
  • History of recurrent clinically significant infection or recurrent bacterial infections
  • Positive quantiferon without documentation of treatment for tuberculosis (TB) infection or documentation of no need for such therapy
  • History of intestinal ulceration or diverticulitis
  • HBcAb positive test, regardless of HBsAb status, will undergo HBV DNA which, if positive, will be excluded. HbcAb positive, HbsAg negative patients with undetectable HBV DNA will receive antiviral prophylaxis throughout the immunosuppressive therapy
  • Hepatitis C antibody positive test at screening
  • Positive test for Human Immunodeficiency Virus (HIV) antibody at screening or historically. Denied consent to HIV testing
  • Cardiovascular or cerebrovascular disease clinically significant
  • Other serious chronic illness (including uncontrolled diabetes mellitus, renal disease, pulmonary disease, major depression)
  • History of sarcoidosis
  • History of IgE-mediated or non-IgE-mediated hypersensitivity
  • History of reactions or anaphylactic allergic severe human monoclonal antibodies, humanized or murine
  • Patients with a history of chronic liver disease or liver disorders: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) above 5 times upper limit of normal (ULN)
  • Absolute neutrophil count (ANC) < 2.0 × 109/L or a platelet count < 100×103/μL
  • Alkaline phosphatase and bilirubin>1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin is<35%)
  • Signs of sight-threatening TED (severe keratopathy, optic neuropathy)
  • Pregnant or breastfeeding woman or woman planning to become pregnant during the study
  • HBsAg positive test
  • Primary or secondary immunodeficiency
  • Splenectomy

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The aim of this study is to evaluate the efficacy and safety of Tocilizumab as second/third line treatment in patients with Active Moderate-to-Severe Corticosteroid-Resistant Thyroid Eye Disease.

The group in the trial

  • Graves' orbitopathy

    Patients with active, moderate to severe TED, without disease improvement after methylprednisolone pulse therapy in an intermediate-dose schedule (starting dose of 0.5 g once weekly for 6 weeks, followed by 0.25 g once weekly for 6 weeks) or high-dose regimens (a starting dose of 0.75 g once weekly for 6 weeks, followed by 0.5 g once weekly for 6 weeks) with or without concomitant radiotherapy.

    Treatment: Tocilizumab

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Efficacy and Safety of Tocilizumab in Patients With Active Moderate-to-Severe Corticosteroid-Resistant Thyroid Eye Disease: Open, Prospective, Observational Study
Publications
Record updated
4 June 2026